ASCO not only offered a peek at developing treatments likely to be commercialized. Its impact also put some companies in the limelight from a business-development perspective.
Digitas Health and Razorfish Health are undergoing an organizational restructure in which the two Publicis-owned siblings will share two newly appointed co-presidents, launch a single global leadership team and develop a variety of centers of excellence.
Following a full-scale realignment of its commercial model in 2009, Novartis will make new adjustments to its US pharmaceutical operations, including a change at the top: Ludwig Hantson, CEO and head of North American pharmaceuticals, will exit the company, a Novartis spokeswoman confirmed.
Drugs.com, a free online drug-information database, will join the WebMD Health Network starting Jan. 1, said WebMD.
An alliance with the nation's largest soft drink maker to sponsor advice on sugar-free alternatives has spurred criticism of the American Academy of Family Physicians (AAFP).
Publicis will acquire Razorfish, a Microsoft-owned digital and interactive shop, for roughly $530 million, according to joint company statements.
Lilly named former Indianapolis mayor Bart Peterson to lead its communications and corporate affairs functions.
Physicians say patient compliance is getting worse, and they're hearing more requests for generic or OTC alternatives to prescribed medications as the economic malaise takes its toll, according to a PriMed survey.
Saatchi & Saatchi Wellness won the US integrated marketing account for Durex following a four-way pitch. The assignment spans advertising, digital, retail and CRM and includes the launch of the new Bare condom.
Pfizer hired onetime Gore advisor turned healthcare think tanker Gregory Simon to head its global policy efforts as the industry gears up for a health reform fight in Washington.
Amylin is cutting 200 sales positions -- around 35% of its sales force -- as it merges its specialty and primary care sales forces into a single organization targeting endocrinologists and diabetes-focused primary care physicians.
Consumers worldwide overwhelmingly prefer medicines that have been around a long time to the latest treatments, and over half prefer generics to branded drugs given the choice, according to a DDB Health survey.
GlaxoSmithKline is buying dermatology specialist Steifel for $3.6 billion.
WebMD pulled within one million unique visitors (UV) of Everyday Health, tightening the UV horserace between the two companies, according to comScore's numbers from March.
Pfizer and GlaxoSmithKline will combine their HIV products and pipelines to form a specialty company, according to an announcement today.
Johnson & Johnson will cut 900 positions at its Ortho-McNeil-Janssen Pharmaceuticals unit by the end of the second quarter.
Genentech and FDA announced the withdrawal of psoriasis treatment Raptiva due to a risk of progressive multifocal leukoencephalopathy (PML), a rare and deadly viral brain infection.
Pfizer announced organizational plans for the company post-Wyeth acquisition, including a new focus on biopharmaceuticals, and the retention of eight Wyeth senior executives.
PhRMA's board of directors elected AstraZeneca chief David Brennan as this year's board chairman and Pfizer chairman and CEO Jeff Kindler chairman-elect.
IMS Health and SDI are seeking a Supreme Court review of an appeals court ruling that restricts the commercial use of prescriber data in the state of New Hampshire.
GlaxoSmithKline said it will broaden its transparency policies to include greater disclosure of its clinical research and the physicians the company works with on clinical trials.
Pfizer named Elizabeth Barrett regional president, US for its Oncology Business Unit, a new position, with responsibility for Pfizer's US oncology sales, field operations and marketing.
Job security for pharma sales reps is looking bleak, going by the results of a ZS Associates study. The survey found that the number of US reps has plummeted 10% since 2007 to 92,000, and the management consultancy projects a further decline, to 75,000 by 2012.
Iowa's state Senate passed a healthcare bill containing some of the toughest restrictions on drug company contacts with physicians yet.
IMS said US prescription drug sales grew 1.3% in 2008 to $291 billion amid increased use of generics, lower sales of new products and slackening consumer demand resulting from the economic downturn.
In just the first three months of 2009, several of the largest companies in the industry announced mergers that will change the face of an industry dogged by sluggish pipelines.
Roche will buy all remaining shares of Genentech at $95 dollars apiece, or $46.8 billion total, the companies announced in a joint statement. Prior to the deal, Roche held 56% of the company's shares.
Advanstar's Debby Savage and Pharmaceutical Media Inc.'s Gina Bennicasa won the Association of Medical Media's 17th annual Nexus Representatives of the Year Awards, honoring outstanding sales professionals in medical publishing.
Bristol-Myers Squibb (BMS) has created an executive committee of four, tasked with leading company strategy and development.
Cline, Davis & Mann is going global with the launch of CDM World Agency, an international healthcare agency network with offices in Europe and Brazil and plans to expand into China, Japan, Mexico and Canada.
Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.